Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
KEYWORDS: prasugrel, clopidogrel, patients, group, coronary, clinical, assessment, assessment group, committee, myocardial, trial, acute, treatment, acute coronary, intervention

clopidogrel. The Committee also heard from the clinical specialists that there was variation in opinion among clinicians in England as to which of prasugrel, ticagrelor or clopidogrel should be considered the standard treatment for all patients with STEMI who have a percutaneous coronary intervention because of the chance of increased bleeding with these treatments. The Committee recognised that antiplatelet therapy such as prasugrel was a valued treatment option. Prasugrel compared with clopidogrel 4.3.2 The Committee considered the evidence presented by the manufacturer and the Assessment Group on the clinical effectiveness of prasugrel compared with clopidogrel for the treatment of acute coronary syndromes in people having percutaneous coronary intervention. The Committee noted that both the manufacturer and the Assessment Group had identified 1 randomised controlled trial (TRITON-TIMI 38) and that this trial had been the main source of evidence for NICE's technology appraisal guidance 182 on prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention. The Committee noted that both the manufacturer and the Assessment Group had stated that no significant new evidence had become available since the publication of the previous appraisal comparing prasugrel with clopidogrel. The Committee heard from one of the clinical specialists that although
